Literature DB >> 17321998

Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.

Seiichi Okabe, Tetsuzo Tauchi, Yuko Ishii, Daigo Akahane, Kousuke Nunoda, Seiko Honda, Tomoiku Takaku, Kazuma Ohyashiki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17321998     DOI： 10.1532/IJH97.06187

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  8 in total

1.  Discontinuation of imatinib therapy after achieving a molecular response.

Authors:  Jorge Cortes; Susan O'Brien; Hagop Kantarjian
Journal:  Blood       Date:  2004-10-01       Impact factor: 22.113

2.  Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients.

Authors:  M Sumi; T Tauchi; G Sashida; N Shoji; A Gotoh; Y Itoh; K Miyazawa; Y Kimura; J H Ohyashiki; K Ohyashiki
Journal:  Clin Lab Haematol       Date:  2005-12

3.  Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.

Authors:  Serena Merante; Ester Orlandi; Paolo Bernasconi; Silvia Calatroni; Marina Boni; Mario Lazzarino
Journal:  Haematologica       Date:  2005-07       Impact factor: 9.941

4.  High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.

Authors:  Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Francis Giles; Mary Beth Rios; Jianqin Shan; Laurie Letvak; Deborah Thomas; Stefan Faderl; Alessandra Ferrajoli; Jorge Cortes
Journal:  Blood       Date:  2003-12-24       Impact factor: 22.113

5.  Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.

Authors:  Takehiro Higashi; Junichi Tsukada; Chiaki Kato; Atsushi Iwashige; Takamitsu Mizobe; Shinichiro Machida; Hiroaki Morimoto; Ryosuke Ogawa; Yoko Toda; Yoshiya Tanaka
Journal:  Am J Hematol       Date:  2004-07       Impact factor: 10.047

6.  Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia.

Authors:  Waleed Ghanima; Johannes Kahrs; Tobias Gedde Dahl; Geir E Tjonnfjord
Journal:  Eur J Haematol       Date:  2004-06       Impact factor: 2.997

7.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

8.  Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission.

Authors:  Michael J Mauro; Brian J Druker; Richard T Maziarz
Journal:  Leuk Res       Date:  2004-05       Impact factor: 3.156
  8 in total
  1 in total

Review 1.  Molecular monitoring.

Authors:  Simona Soverini; Gianantonio Rosti; Michele Baccarani; Giovanni Martinelli
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.